Search clinical trials for: Abrocitinib tablet

Total 7483 results

University of Erlangen-Nürnberg Medical School

Active, not recruiting

Effect of Baricitinib Treatment on Peripheral Bone in RA (BAREBONE)

Rheumatoid Arthritis | Bone Density | Finger Joints

Germany
IRCCS Policlinico S. Matteo

Unknown

Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial (BREATH)

Corona Virus Infection
Eli Lilly and Company

Completed

Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

Healthy Volunteers

United States
Overseas Pharmaceuticals, Ltd.
GX pharma technology (beijing) Co., Ltd

Active, not recruiting

An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.

Partial Seizure

China
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
Duke University
Eli Lilly and Company; National Institute on Minority Health and Health Disparities...

Recruiting

Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease (JUSTICE)

Chronic Kidney Diseases

United States
Eli Lilly and Company

Active, not recruiting

A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

Aicardi Goutieres Syndrome | Nakajo-Nishimura Syndrome | Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome | STING-Associated Vasculopathy With Onset in Infancy

Japan
Wright State Physicians

Completed

Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

Allergic Contact Dermatitis

United States
University Hospital, Brest
Eli Lilly and Company

Completed

BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica (BACHELOR)

Polymyalgia Rheumatic (PMR)

France
University Hospital of Patras

Completed

Tocilizumab Versus Baricitinib in Patients With Severe COVID-19

COVID-19

Greece
Eli Lilly and Company
Incyte Corporation

Terminated

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis (BREEZE-AD6)

Atopic Dermatitis

United States, Puerto Rico, Canada
Eli Lilly and Company

Completed

A Study of Baricitinib in Healthy Japanese Participants

Healthy Participants

Japan
Beijing Tiantan Hospital
NeuroDawn Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy (ESPRIT)

Ischemic Stroke, Acute

China
Vaxart

Completed

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines (VXA-NVV-103)

Norovirus Infection

United States
Pirogov Russian National Research Medical University
City Clinical Hospital No.52 of Moscow Healthcare Department

Completed

COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

COVID-19 | Mild to Moderate

Russian Federation
Eli Lilly and Company

No longer available

Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE) | Juvenile Dermatomyositis (JDM) | Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI) | Aicardi-Goutières Syndrome (AGS)

United States, United Kingdom
Eli Lilly and Company

Completed

A Study of Baricitinib (LY3009104) in Participants With COVID-19 (COV-BARRIER)

COVID-19

United States, Spain, India, Germany, Puerto Rico, Brazil, Korea, Republic of, Argentina, Italy, Japan, Mexico, Russian Federation, United Kingdom
Eli Lilly and Company
Incyte Corporation

Completed

Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis (BREEZE-AD2)

Atopic Dermatitis

Spain, Australia, Switzerland, Israel, Korea, Republic of, Japan, Poland, Argentina, Austria, Hungary
Eli Lilly and Company

Completed

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, Spain, Taiwan, France, Japan, Mexico, Puerto Rico, Austria, Poland, Korea, Republic of, Argentina, Romania
Eli Lilly and Company

Completed

A Study of LY3009104(Baricitinib) for Healthy Subjects

Healthy Volunteer

United States
Eli Lilly and Company

Completed

A Study of Baricitinib (LY3009104) in Healthy Chinese Participants

Healthy

China
University of California, Los Angeles

Recruiting

Metformin Treatment in Progressive Multiple Sclerosis

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Bausch Health Americas, Inc.

Completed

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

Liver Cirrhosis

United States, Russian Federation
Tang-Du Hospital

Not yet recruiting

Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

Traumatic Brain Injury

China
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

Pharmacokinetics

Germany
Pfizer

Completed

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Atopic Dermatitis

Spain, Taiwan, United States, Korea, Republic of, Poland, Canada, Australia, Hungary, Germany, Latvia, Finland, Chile, Bulgaria, Slovakia, Italy
Assiut University

Not yet recruiting

Evaluation Safety ,Efficacy Baricitinib Plus Excimer Light Versus Excimer Light Alone in Non Segmental Vitiligo

Vitiligo, Generalized
Eli Lilly and Company

Recruiting

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)

Skin Diseases | Pathological Conditions, Anatomical | Alopecia | Hypotrichosis | Hair Diseases | Areata Alopecia

United States, Japan, Taiwan, Korea, Republic of, Spain, Germany, France, Mexico, Canada, Poland, Australia, Hungary, Argentina
Eli Lilly and Company

Recruiting

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

Systemic Juvenile Idiopathic Arthritis

Belgium, Spain, India, Italy, Czechia, Japan, Austria, France, United Kingdom, Brazil, Mexico, Israel, Poland, Argentina, Denmark, Turkey
Eli Lilly and Company
Incyte Corporation

Completed

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II) (BRAVE II)

Systemic Lupus Erythematosus

United States, Spain, Korea, Republic of, Serbia, Poland, France, Italy, Japan, South Africa, India, Argentina, Chile, Philippines, Romania, Colombia
Incepta Pharmaceuticals Ltd

Not yet recruiting

Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19

Covid19

Bangladesh
University of Colorado, Denver

Withdrawn

Safety and Efficacy of Baricitinib for COVID-19

COVID-19

United States
University Hospital, Bordeaux

Completed

Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo (BARVIT)

Vitiligo

France
Eli Lilly and Company
Incyte Corporation

Completed

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Skin Diseases | Psoriasis | Skin Diseases, Papulosquamous

Canada, Japan, United States, Puerto Rico
Stallergenes Greer

Completed

Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma

Asthma | House Dust Mite Allergy

France, Germany, Poland
Dong-A ST Co., Ltd.

Completed

A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)

Chronic Myeloid Leukemia | Gastrointestinal Stromal Tumor

Korea, Republic of
Massachusetts General Hospital

Recruiting

Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial (NADALS)

Amyotrophic Lateral Sclerosis | Alzheimer Disease | Mild Cognitive Impairment

United States
AstraZeneca

Completed

A Bioavailability Study Comparing 3 Different AZD1981 Tablets

Healthy

Sweden
Vaxart

Completed

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

Norovirus Gastroenteritis

United States
RH Nanopharmaceuticals
Center for Bioequivalence Studies and Clinical Research

Completed

Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers

Pharmacokinetics | Tolerability | Safety

Pakistan
Prof. Dr. Stephan Weidinger

Recruiting

Molecular Signatures in Inflammatory Skin Disease (MSID)

Psoriasis | Atopic Dermatitis

Germany
Assiut University

Recruiting

Use of Baricitenib to Maintain of Remission

Nephritis | Lupus or SLE

Egypt
Vanderbilt University Medical Center
Yale University; Emory University; University of California, San Francisco; Vanderbilt... and other collaborators

Not yet recruiting

REVERSE-Long COVID-19 With Baricitinib Study (REVERSE-LC)

Post-Acute COVID-19 Syndrome

United States
Eli Lilly and Company
Incyte Corporation

Completed

A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis (BREEZE-AD7)

Atopic Dermatitis

Spain, Australia, Korea, Republic of, Poland, Italy, Germany, Argentina, Austria, Japan, Taiwan
Eli Lilly and Company
Incyte Corporation

Completed

A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis (BREEZE-AD3)

Atopic Dermatitis

Spain, Korea, Republic of, France, Taiwan, India, Australia, Germany, Japan, Italy, Switzerland, Israel, Argentina, Austria, Czechia, Hungary, Mexico, Poland, Russian Federation, Denmark
Beijing Tiantan Hospital
NeuroDawn Pharmaceutical Co., Ltd.

Recruiting

Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion (CRYSTAL)

Acute Ischemic Stroke | Large Vessel Occlusion | Reperfusion

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
Fabrizio Cantini

Completed

Baricitinib Therapy in COVID-19

Pneumonia | COVID

Italy
Adeline Vanderver, MD
Eli Lilly and Company

Completed

JAK Inhibitor Treatment in AGS

Aicardi Goutieres Syndrome

United States
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States

Search clinical trials for: Abrocitinib tablet

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations